AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Progenics PharmaceuticalsNewLink GeneticsBeyondspringTrillium TherapeuticsSatsuma Pharmaceuticals
SymbolNASDAQ:PGNXNASDAQ:NLNKNASDAQ:BYSINASDAQ:TRILNASDAQ:STSA
Price Information
Current Price$4.24N/A$15.59$7.68$24.66
52 Week RangeBuySellBuyBuyBuy
Beat the Market™ Rank
Overall Score1.40.61.31.61.7
Analysis Score3.50.03.53.33.5
Community Score2.62.82.63.02.4
Dividend Score0.00.00.00.00.0
Ownership Score1.00.00.01.02.0
Earnings & Valuation Score0.00.00.60.60.6
Analyst Ratings
Consensus RecommendationBuySellBuyBuyBuy
Consensus Price Target$12.00N/A$29.67$10.00$33.00
% Upside from Price Target183.02% upsideN/A90.29% upside30.21% upside33.82% upside
Trade Information
Market Cap$376.71 million$505.05 million$474.05 million$565.70 million$455.60 million
Beta1.891.171.172.18N/A
Average Volume852,209547,54049,6704,105,75249,299
Sales & Book Value
Annual Revenue$34.99 million$940,000.00N/A$120,000.00N/A
Price / Sales10.490.00N/A5,339.90N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.54 per share$2.11 per share$1.12 per share($0.86) per share$6.64 per share
Price / Book7.850.00N/A-8.93N/A
Profitability
Net Income$-68,550,000.00$-42,990,000.00$-38,080,000.00$-41,620,000.00$-28,170,000.00
EPS($0.80)($1.03)($1.55)($1.38)($4.80)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-180.28%-4,592.84%N/AN/AN/A
Return on Equity (ROE)-129.46%-41.50%-431.19%-371.12%N/A
Return on Assets (ROA)-53.23%-33.95%-171.68%-50.63%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.99%N/A0.11%N/A0.02%
Current Ratio2.12%7.98%4.06%6.06%15.05%
Quick Ratio2.12%7.98%4.06%6.06%15.05%
Ownership Information
Institutional Ownership Percentage70.96%32.32%6.60%73.21%79.40%
Insider Ownership Percentage4.26%12.70%N/AN/A39.20%
Miscellaneous
Employees7955N/AN/A11
Shares Outstanding86.60 million37.33 million27.89 million83.44 million17.39 million
Next Earnings Date8/14/2020 (Estimated)N/A7/8/2020 (Estimated)8/11/2020 (Estimated)8/11/2020 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.